


CSI RESEARCH SEMINAR




Prof. David Weinstock

Department of Medical Oncology
Dana Farber Cancer Institute


"Strategies to Understand and Advance Cancer Cure"

ABSTRACT



Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure. Advances from the Weinstock laboratory have identified both tumor cell-autonomous and immune-mediated mechanisms that likely contribute to curative therapy in patients. These will be reviewed and new data outlining efforts to interrogate and target individual MRD cells will be described.

BIOGRAPHY



Dr. David Weinstock is the Lavine Family Professor at Dana-Farber Cancer Institute and a Professor of Medicine and Pediatrics at Harvard Medical School. He completed fellowship training in Medical Oncology and Infectious Diseases at Memorial Sloan-Kettering Cancer Center. He joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital in 2008, where he is a medical oncologist and directs a translational research program focused on novel therapeutics for lymphoid malignancies. He developed the Public Repository of Xenografts (<http://www.PRoXe.org>), which shares patient-derived xenograft models around the world. He is a National Cancer Institute Outstanding Investigator and leads the Leukemia Program for the Dana-Farber/Harvard Cancer Center. He has mentored several junior scientists who now lead their own scientific groups at Harvard and elsewhere. In January 2022, he became the Vice President of Discovery Oncology at MSD/Merck.



FRIDAY, 15 JULY 2022

3.30PM - 4.30PM

CRC AUDITORIUM, MD11 (LEVEL 1)

CHAIR: A/PROF. TAKAOMI SANDA